NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 4.3% and is now trading at $34.30.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) posted its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.02. The biotechnology company had revenue of $16.60 million for the quarter, compared to the consensus estimate of $22.23 million. Regenxbio had a negative net margin of 197.23% and a negative return on equity of 27.84%. The company's quarterly revenue was up 110.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.04) earnings per share.
View Regenxbio's earnings history.

6 brokers have issued 1-year price targets for Regenxbio's stock. Their forecasts range from $37.00 to $100.00. On average, they anticipate Regenxbio's share price to reach $60.00 in the next year. This suggests a possible upside of 74.9% from the stock's current price.
View analysts' price targets for Regenxbio.

Media coverage about RGNX stock has been trending positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Regenxbio earned a news impact score of 2.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Immunovant (IMVT), SpringWorks Therapeutics (SWTX) and Mesoblast (MESO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Botty Investors LLC (0.81%), UBS Group AG (0.81%), Principal Financial Group Inc. (0.67%), Swiss National Bank (0.19%), P.A.W. Capital Corp (0.19%) and New York State Teachers Retirement System (0.13%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista.
View institutional ownership trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, WINTON GROUP Ltd, Assenagon Asset Management S.A., Hancock Whitney Corp, Texas Permanent School Fund, Arizona State Retirement System, and Liberty One Investment Management LLC. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, and Vittal Vasista.
View insider buying and selling activity for Regenxbio.

RGNX stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Essex Investment Management Co. LLC, Mackay Shields LLC, New York State Teachers Retirement System, Principal Financial Group Inc., Swiss National Bank, ProShare Advisors LLC, and Exane Derivatives.
View insider buying and selling activity for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $34.30.

Regenxbio has a market capitalization of $1.28 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]